Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Expects Tysabri To Capture 50% Of Expanded Multiple Sclerosis Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Elan says its goal is to grow the MS market, not to destroy Tysabri partner Biogen Idec's Avonex franchise. Patient uptake for Tysabri is "far beyond what we thought it would be," Elan says. The firm is also encouraged by physicians' acceptance of one-year trial data and a desire to establish infusion centers.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS061048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel